{"id":3964,"date":"2026-10-28T09:00:00","date_gmt":"2026-10-28T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3964"},"modified":"2026-10-28T20:49:42","modified_gmt":"2026-10-29T00:49:42","slug":"vav1-degrader-enters-second-phase-ii-disease","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3964","title":{"rendered":"VAV1 Degrader Enters Second Phase II Disease"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Monte Rosa Therapeutics; Novartis<\/p>\n

Event Type<\/strong><\/p>\n

Phase II initiation and milestone<\/p>\n

Modality<\/strong><\/p>\n

Molecular-glue degrader<\/p>\n

Asset<\/strong><\/p>\n

MRT-6160 (DDY391)<\/p>\n

Target<\/strong><\/p>\n

VAV1<\/p>\n

Disease Area<\/strong><\/p>\n

Psoriatic arthritis; Sj\u00f6gren disease<\/p>\n

Summary<\/h4>\n

Monte Rosa said on 28 October that Novartis initiated a second Phase II study of licensed VAV1 molecular-glue degrader MRT-6160, also called DDY391, in psoriatic arthritis. This is development expansion and a milestone event, not an efficacy readout.<\/p>\n

The new study follows a September 2026 Phase II start in Sj\u00f6gren disease. Monte Rosa reported a contractually associated milestone, without disclosing its amount in the current release. The program targets VAV1, an intracellular immune-signaling protein. No new patient response, safety or pharmacodynamic dataset was disclosed on 28 October.<\/p>\n

Deep Analysis<\/h4>\n

Moving into a second immune-mediated disease tests whether VAV1 depletion can support a broadly useful oral anti-inflammatory mechanism. Psoriatic arthritis offers measurable joint, skin and functional endpoints, but disease heterogeneity and existing biologics raise the evidence bar. Molecular-glue translation depends on tissue exposure, selective neosubstrate recruitment, sustained protein depletion and immune-suppression safety. A trial start indicates sponsor commitment, not proof of therapeutic benefit. The existing global Novartis license also means this is not a newly signed deal.<\/p>\n

Company and Product Background<\/h4>\n

VAV1 is a hematopoietic signaling adaptor involved in T-cell activation. MRT-6160 is designed to induce VAV1 degradation through an E3-ligase recruitment mechanism.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> Novartis sees sufficient early safety and mechanism evidence to broaden clinical testing; a second Phase II supports that modestly.<\/li>\n
  • Interpretation B:<\/strong> the expansion reflects portfolio optionality before efficacy is known.<\/li>\n
  • Upgrade<\/strong> with blinded clinical endpoints and exposure-response data. Downgrade<\/strong> with inadequate VAV1 degradation or infection signals. A negative controlled study at target-engaging exposure would falsify<\/strong> the broad-disease thesis.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: this is useful clinical progression for molecular-glue degradation, with no new efficacy claim.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: neutral pending data. Confidence in Facts: high. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Monte Rosa said on 28 October that Novartis initiated a second Phase II study of licensed VAV1 molecular-glue degrader MRT-6160, also called DDY391, in psoriatic arthritis. This is development expansion and a milestone event,…<\/p>\n","protected":false},"author":1,"featured_media":3969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[901,900,1274,48,1275],"class_list":["post-3964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-molecular-glue-degrader","tag-monte-rosa-therapeutics","tag-mrt-6160","tag-novartis","tag-vav1"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3964"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3964\/revisions"}],"predecessor-version":[{"id":3980,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3964\/revisions\/3980"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3969"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}